“May 2 (Reuters) – Gilead Sciences Inc on Thursday said almost all patients taking a fixed-dose combination of two of its experimental hepatitis C drugs appeared to have eliminated the liver virus after either 8 weeks or 12 weeks of treatment in a small mid-stage study.
The data could help Gilead, whose shares rose 4 percent, remain in the lead among drugmakers racing to develop better medicines for the potentially dangerous condition that also require far shorter durations of treatment…”
If you enjoy the content at iBankCoin, please follow us on Twitter
